Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma

Clinical Endocrinology

Volumn 65, Issue 2, 2006, Pages 215-222

  Papewalis, Claudia ^a   Fassnacht, Martin ^d   Willenberg, Holger S ^a   Domberg, Julia ^a   Fenk, Roland ^b   Rohr, Ulrich Peter ^a   Schinner, Sven ^a   Bornstein, Stefan R ^c   Scherbaum, Werner A ^a   Schott, Matthias ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CYTOKINE; GRANZYME B; MACROGOL; MITOTANE; TUMOR ANTIGEN; TUMOR MARKER;

ADRENAL CORTEX CARCINOMA; ADULT; ANGIOGENESIS; ANTIGEN SPECIFICITY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SIZE; CANCER SURGERY; CASE REPORT; CELL FUSION; CELL LYSATE; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG SCREENING; FLOW CYTOMETRY; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTE PROLIFERATION; MALE; MEMORY T LYMPHOCYTE; MOLECULAR STABILITY; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SKIN MANIFESTATION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TREATMENT OUTCOME; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; DENDRITIC CELLS; FATAL OUTCOME; FLOW CYTOMETRY; HUMANS; HYBRIDOMAS; HYPERSENSITIVITY, DELAYED; INJECTIONS; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; MITOTANE; TREATMENT FAILURE;

EID: 33746036541     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2006.02576.x     Document Type: Article

References (45)

1. Allolio, B., Hahner, S., Weismann, D. & Fassnacht, M. (2004) Management of adrenocortical carcinoma. Clinical Endocrinology, 60, 273-287.
2. Icard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J.F. & Proye, C. (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World Journal of Surgery, 25, 891-897.
3. Luton, J.P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.H., Louvel, A., Chapuis, Y. & Blondeau, P. (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. New England Journal of Medicine, 322, 1195-1201.
4. Vassilopoulou-Sellin, R. & Schultz, P.N. (2001) Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer, 92, 1113-1121.
5. Pommier, R.F. & Brennan, M.F. (1992) An eleven-year experience with adrenocortical carcinoma. Surgery, 112, 963-970.
6. Ahlman, H., Khorram-Manesh, A., Jansson, S., Wangberg, B., Nilsson, O., Jacobsson, C.E. & Lindstedt, S. (2001) Cytotoxic treatment of adrenocortical carcinoma. World Journal of Surgery, 25, 927-933.
7. Hahner, S. & Fassnacht, M. (2005) Mitotane for adrenocortical carcinoma treatment. Current Opinion in Investigational Drugs, 6, 386-394.
8. Wooten, M.D. & King, D.K. (1993) Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer, 72, 3145-3155.
9. Banchereau, J. & Steinman, R.M. (1998) Dendritic cells and the control of immunity. Nature, 392, 245-252.
10. Gilboa, E. (2004) The promise of cancer vaccines. Nature Reviews. Cancer, 4, 401-411.
11. Schuler, G., Schuler-Thurner, B. & Steinman, R.M. (2003) The use of dendritic cells in cancer immunotherapy. Current Opinion in Immunology, 15, 138-147.
12. Mayordomo, J.I., Zorina, T., Storkus, W.J., Zitvogel, L., Celluzzi, C., Falo, L.D., Melief, C.J., Ildstad, S.T., Kast, W.M. & DeLeo, A.B. (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Medicine, 1, 1297-1302.
13. Nair, S.K., Hull, S., Coleman, D., Gilboa, E., Lyerly, H.K. & Morse, M.A. (1999) Induction of carcinoembryonic antigen (CEA) - specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. International Journal of Cancer, 82, 121-124.
14. Paglia, P., Chiodoni, C., Rodolfo, M. & Colombo, M.P. (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. Journal of Experimental Medicine, 183, 317-322.
15. Schott, M., Seissler, J., Lettmann, M., Fouxon, V., Scherbaum, W.A. & Feldkamp, J. (2001) Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. Journal of Clinical Endocrinology and Metabolism, 86, 4965-4969.
16. Schott, M., Feldkamp, J., Klucken, M., Kobbe, G., Scherbaum, W.A. & Seissler, J. (2002) Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. Cancer Immunology, Immunotherapy, 51, 663-668.
17. Albert, M.L., Sauter, B. & Bhardwaj, N. (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature, 392, 86-89.
18. Ashley, D.M., Faiola, B., Nair, S., Hale, L.P., Bigner, D.D. & Gilboa, E. (1997) Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. Journal of Experimental Medicine, 186, 1177-1182.
19. Fields, R.C., Shimizu, K. & Mule, J.J. (1998) Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proceedings of the National Academy of Sciences of the USA, 95, 9482-9487.
20. Schott, M., Feldkamp, J., Schattenberg, D., Seissler, J. & Scherbaum, W.A. (1999) Dendritic cell immunotherapy in disseminated parathyroid carcinoma. Lancet, 353, 1188-1189.
21. Gong, J., Chen, D., Kashiwaba, M. & Kufe, D. (1997) Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Medicine, 3, 558-561.
22. Hayashi, T., Tanaka, H., Tanaka, J., Wang, R., Averbook, B.J., Cohen, P.A. & Shu, S. (2002) Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clinical Immunology, 104, 14-20.
23. Gong, J., Koido, S., Chen, D., Tanaka, Y., Huang, L., Avigan, D., Anderson, K., Ohno, T. & Kufe, D. (2002) Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood, 99, 2512-2517.
24. Gong, J., Chen, D., Kashiwaba, M., Li, Y., Chen, L., Takeuchi, H., Qu, H., Rowse, G.J., Gendler, S.J. & Kufe, D. (1998) Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proceedings of the National Academy of Sciences of the USA, 95, 6279-6283.
25. Gong, J., Avigan, D., Chen, D., Wu, Z., Koido, S., Kashiwaba, M. & Kufe, D. (2000) Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proceedings of the National Academy of Sciences of the USA, 97, 2715-2718.
26. Avigan, D., Vasir, B., Gong, J., Borges, V., Wu, Z., Uhl, L., Atkins, M., Mier, J., McDermott, D., Smith, T., Giallambardo, N., Stone, C., Schadt, K., Dolgoff, J., Tetreault, J.C., Villarroel, M. & Kufe, D. (2004) Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clinical Cancer Research, 10, 4699-4708.
27. Berger, T.G., Feuerstein, B., Strasser, E., Hirsch, U., Schreiner, D., Schuler, G. & Schuler-Thurner, B. (2002) Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. Journal of Immunological Methods, 268, 131-140.
28. Jonuleit, H., Kuhn, U., Muller, G., Steinbrink, K., Paragnik, L., Schmitt, E., Knop, J. & Enk, A.H. (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. European Journal of Immunology, 27, 3135-3142.
29. Schott, M., Feldkamp, J., Schattenberg, D., Krueger, T., Dotzenrath, G., Seissler, J. & Scherbaum, W.A. (2000) Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. European Journal of Endocrinology, 142, 300-306.
30. Fassnacht, M., Hahner, S., Beuschlein, F., Klink, A., Reincke, M. & Allolio, B. (2000) New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line. European Journal of Clinical Investigations, 30 (Suppl. 3), 76-82.
31. Limon, A., Briones, J., Puig, T., Carmona, M., Fornas, O., Cancelas, J.A., Nadal, M., Garcia, J., Rueda, F. & Barquinero, J. (1997) High-titer retroviral vectors containing the enhanced green fluorescent protein gene for efficient expression in hematopoietic cells. Blood, 90, 3316-3321.
32. Brostjan, C., Bayer, A., Zommer, A., Gornikiewicz, A., Roka, S., Benko, T., Yaghubian, R., Jakesz, R., Steger, G., Gnant, M., Friedl, J. & Stift, A. (2003) Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. Cancer, 98, 2291-2301.
33. Ito, H., Oshita, F., Kameda, Y., Suzuki, R., Ikehara, M., Arai, H., Mitsuda, A., Saito, H., Yamada, K., Noda, K. & Nakayama, H. (2002) Expression of vascular endothelial growth factor and basic fibroblast growth factor in small adenocarcinomas. Oncology Report, 9, 119-123.
34. Lanchou, J., Corbel, M., Tanguy, M., Germain, N., Boichot, E., Theret, N., Clement, B., Lagente, V. & Malledant, Y. (2003) Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients. Critical Care Medicine, 31, 536-542.
35. Molica, S., Vitelli, G., Levato, D., Giannarelli, D., Vacca, A., Cuneo, A., Ribatti, D. & Digiesi, G. (2004) Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression. European Journal of Haematology, 73, 36-42.
36. Zhao, H., Grossman, H.B., Delclos, G.L., Hwang, L.Y., Troisi, C.L., Chamberlain, R.M., Chenoweth, M.A., Zhang, H., Spitz, M.R. & Wu, X. (2005) Increased plasma levels of angiogenin and the risk of bladder carcinoma: from initiation to recurrence. Cancer, 104, 30-35.
37. Ortmann, D., Hausmann, J., Beuschlein, F., Schmenger, K., Stahl, M., Geissler, M. & Reincke, M. (2004) StAR-directed immunotherapy protects against tumor growth of StAR expressing Sp2-0 cells in a rodent adrenocortical carcinoma model. Endocrinology, 145, 1760-1766.
38. Zenkert, S., Schubert, B., Fassnacht, M., Beuschlein, F., Allolio, B. & Reincke, M. (2000) Steroidogenic acute regulatory protein mRNA expression in adrenal tumours. European Journal of Endocrinology, 142, 294-299.
39. Nestle, P.O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. & Schadendorf, D. (1998) Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells. Nature Medicine, 4, 328-332.
40. Holtl, L., Zelle-Rieser, C., Gander, H., Papesh, C., Ramoner, R., Bartsch, G., Rogatsch, H., Barsoum, A.L., Coggin, J.H. Jr & Thurnher, M. (2002) Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clinical Cancer Research, 8, 3369-3376.
41. Cerundolo, V., Hermans, I.F. & Salio, M. (2004) Dendritic cells: a journey from laboratory to clinic. Nature Immunology, 5, 7-10.
42. Schuler-Thurner, B., Schultz, E.S., Berger, T.G., Weinlich, G., Ebner, S., Woerl, P., Bender, A., Feuerstein, B., Fritsch, P.O., Romani, N. & Schuler, G. (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide- loaded monocyte-derived dendritic cells. Journal of Experimental Medicine, 195, 1279-1288.
43. Schultz, E.S., Schuler-Thurner, B., Stroobant, V., Jenne, L., Berger, T.G., van der Thielemanns, K., Bruggen, P. & Schuler, G. (2004) Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. Journal of Immunology, 172, 1304-1310.
44. Timmerman, J.M., Czerwinski, D.K., Davis, T.A., Hsu, F.J., Benike, C., Hao, Z.M., Taidi, B., Rajapaksa, R., Caspar, C.B., Okada, C.Y., van Beckhoven, A., Liles, T.M., Engleman, E.G. & Levy, R. (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood, 99, 1517-1526.
45. Akasaki, Y., Kikuchi, T., Homma, S., Abe, T., Kote, D. & Ohno, T. (2001) Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. Journal of Immunotherapy, 24, 106-113.